Key facts
- This page summarizes Iris Roth's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Mar 2023, 15:30.
Iris Roth - 01 Mar 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ZNTL
- Reported as of
- 01 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2023, 15:30:11 UTC
- Prior SEC filing
- 13 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrea Paul, attorney-in-fact for Iris Roth
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Iris Roth filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 02 Mar 2023.
Change
- Previous filing in this sequence was filed on 13 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZNTL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +52,500
- Change %
- Price
- $0.000000
- Shares after
- 52,500
- Date
- 01 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZNTL
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +297,500
- Change %
- Price
- $0.000000
- Shares after
- 297,500
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 297,500
- Exercise price
- $18.87
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer.
Footnote F2
The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.